0RQE Stock Chart & Stats
CHF5.34
CHF0.47(7.54%)
At close: 4:00 PM EDT
CHF5.34
CHF0.47(7.54%)
Day’s Range― - ―
52-Week RangeCHF2.82 - CHF7.55
Previous CloseN/A
Volume312.22K
Average Volume (3M)136.71K
Market Cap
CHF1.19B
Enterprise ValueCHF3.01K
Total Cash (Recent Filing)CHF88.69M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Oct 29, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding269,055,730
10 Day Avg. Volume133,644
30 Day Avg. Volume136,709
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF5.75Price Target Upside7.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.47
Revenue Forecast (FY)CHF215.59M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginAn approximately 81% gross margin indicates that Idorsia’s products and commercial rights can generate substantial gross profit before operating costs. If maintained, this provides a strong economic base for funding research, commercialization, and future growth as the portfolio develops.
Diversified Revenue ModelIdorsia combines direct or distributed medicine sales with partnerships and licensing, creating multiple routes to monetize its scientific assets. This model can provide product revenue while also offering milestone and royalty opportunities when partners advance or commercialize medicines.
Proprietary Drug PipelineA proprietary small-molecule pipeline spanning multiple therapeutic areas gives Idorsia several potential avenues for long-term value creation. Multiple candidates and selected marketed products can reduce reliance on a single indication, provided development and commercialization progress.
Bears Say
Highly Stressed Balance SheetMaterially negative equity and debt that is large relative to the asset base create a severe financial risk profile. This reduces flexibility to fund development internally, limits resilience if operating performance weakens, and may increase dependence on future financing or strategic transactions.
Persistent Cash BurnSustained negative operating and free cash flow means the business is consuming cash rather than self-funding its operations and pipeline. If this trend persists, Idorsia may need ongoing external funding, which can constrain investment choices and increase financial pressure over the coming quarters.
Deep Operating LossesFalling TTM revenue alongside deeply negative operating and net margins shows that the current commercial base is not covering the company’s cost structure. This weak earnings profile limits internal funding capacity and makes a durable return to profitability dependent on improved revenue or substantial cost control.
0RQE FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest share price was CHF2.81 and its highest was CHF7.55 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.19B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 28 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Jul 30, 2026. The company reported -CHF0.17 earnings per share for the quarter, beating the consensus estimate of -CHF0.195 by CHF0.025.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd does not currently pay dividends.
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.28.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 269,055,730 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.17 in its last earnings report, beating expectations of -CHF0.195. Following the earnings report the stock price went down -5.64%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in GB:0RQE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
0RQE Stock 12 Month Forecast
Average Price Target
CHF5.75
▲(7.68% Upside)
Technical Analysis
Addex Therapeutics
―
Molecular Partners AG
―
Basilea Pharmaceutica
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―